BioMarin Pharmaceutical Inc.
US ˙ NasdaqGS ˙ US09061G1013

SecurityBMRN / BioMarin Pharmaceutical Inc.
InstitutionAlliancebernstein L.p.
Latest Disclosed Ownership248,157 shares
Latest Disclosed Value $ 14,747,971
Alliancebernstein L.p. ownership in BMRN / BioMarin Pharmaceutical Inc.

On May 15, 2026 - Alliancebernstein L.p. filed a 13F-HR form disclosing ownership of 248,157 shares of BioMarin Pharmaceutical Inc. (US:BMRN) valued at $14,018,389 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 264,916 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of -6.33% during the quarter. The current value of the position is $13,564,262 USD.

Alliancebernstein L.p. has a history of taking positions in derivatives of the underlying security (BMRN) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

BMRN / BioMarin Pharmaceutical Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 248,157 -16,759 -6.33 14,748 -6.33 0.0048
2026-02-17 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 264,916 -76,875 -22.49 15,744 -14.95 0.0050
2025-11-14 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 341,791 68,286 24.97 18,511 23.13 0.0058
2025-08-14 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 273,505 -45,474 -14.26 15,035 -33.32 0.0049
2025-05-15 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 318,979 61,594 23.93 22,549 33.29 0.0082
2025-02-12 2024-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 257,385 -22,055 -7.89 16,918 -13.87 0.0057
2024-11-14 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 279,440 -15,204 -5.16 19,642 -19.03 0.0066
2024-08-14 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 294,644 203,137 221.99 24,258 203.53 0.0085
2024-05-14 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 91,507 1,024 1.13 7,992 -8.39 0.0028
2024-02-14 2023-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 90,483 1,762 1.99 8,724 11.13 0.0034
2023-11-14 2023-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 88,721 -64,613 -42.14 7,850 -40.93 0.0033
2023-08-15 2023-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 153,334 -23,357 -13.22 13,291 -22.65 0.0054
2023-05-15 2023-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 176,691 88,833 101.11 17,181 88.97 0.0074
2023-02-15 2022-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 87,858 -4,309 -4.68 9,092 16.37 0.0041
2022-11-15 2022-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 92,167 -137,670 -59.90 7,813 -58.98 0.0038
2022-08-15 2022-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 229,837 48,476 26.73 19,047 36.22 0.0087
2022-05-13 2022-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 181,361 -191,716 -51.39 13,983 -57.58 0.0054
2022-02-14 2021-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 373,077 35,043 10.37 32,961 26.16 0.0117
2021-11-10 2021-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 338,034 184,974 120.85 26,127 104.58 0.0103
2021-07-30 2021-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 153,060 46,174 43.20 12,771 58.23 0.0051
2021-05-06 2021-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 106,886 -311,202 -74.43 8,071 -77.99 0.0035
2021-02-08 2020-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 418,088 117,161 38.93 36,662 60.13 0.0173
2020-11-12 2020-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 300,927 49,403 19.64 22,895 -26.20 0.0123
2020-08-13 2020-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 251,524 150,092 147.97 31,023 261.95 0.0182
2020-05-14 2020-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 101,432 -6,290 -5.84 8,571 -5.90 0.0061
2020-02-18 2019-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 107,722 1,874 1.77 9,108 27.67 0.0052
2019-11-14 2019-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 105,848 -1,121 -1.05 7,134 -22.13 0.0044
2019-08-14 2019-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 106,969 1,032 0.97 9,162 -2.64 0.0057
2019-05-14 2019-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 105,937 -813 -0.76 9,410 3.52 0.0061
2019-02-13 2018-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 106,750 -2,072 -1.90 9,090 -13.86 0.0067
2018-11-08 2018-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 108,822 454 0.42 10,552 3.37 0.0069
2018-08-13 2018-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 108,368 -88,832 -45.05 10,208 -36.15 0.0071
2018-05-14 2018-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 197,200 48,820 32.90 15,987 20.83 0.0116
2018-02-13 2017-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 148,380 31,320 26.76 13,231 21.44 0.0095
2017-11-13 2017-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 117,060 684 0.59 10,895 3.08 0.0082
2017-08-10 2017-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 116,376 2,756 2.43 10,569 5.97 0.0082
2017-05-11 2017-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 113,620 -29 -0.03 9,974 5.94 0.0079
2017-02-13 2016-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 113,649 3,047 2.75 9,415 -7.99 0.0078
2016-11-10 2016-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 110,602 1,250 1.14 10,233 20.28 0.0086
2016-08-11 2016-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 109,352 1,300 1.20 8,508 -4.53 0.0073
2016-05-13 2016-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 108,052 -3,702 -3.31 8,912 -23.87 0.0076
2016-02-16 2015-12-31 13F/A-1 BIOMARIN PHARMACEUTICAL COM 09061G101 111,754 -317 -0.28 11,707 -0.81 0.0100
2016-02-12 2015-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 111,754 11,770
2015-11-13 2015-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 112,071 -921 -0.82 11,803 -23.63 0.0101
2015-08-14 2015-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 112,992 4,685 4.33 15,455 14.51 0.0128
2015-05-13 2015-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 108,307 2,377 2.24 13,497 40.95 0.0109
2015-02-13 2014-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 105,930 -573 -0.54 9,576 24.61 0.0080
2014-11-13 2014-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 106,503 903 0.86 7,685 16.99 0.0065
2014-08-13 2014-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 105,600 1,548 1.49 6,569 -7.44 0.0055
2014-05-13 2014-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 104,052 -580,891 -84.81 7,097 -85.25 0.0061
2014-02-13 2013-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 684,943 -110,404 -13.88 48,131 -16.21 0.0430
2013-11-14 2013-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 795,347 53,367 7.19 57,440 38.76 0.0567
2013-08-13 2013-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 741,980 741,980 41,395 0.0439
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2018-11-08 2018-09-30 13F BIOMARIN PHARMACEUTICAL COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-08-13 2018-06-30 13F BIOMARIN PHARMACEUTICAL COM Call 40,000 3,768 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.